| Literature DB >> 32875786 |
Silvia Varela-Aramburu1,2, Chandradhish Ghosh1, Felix Goerdeler1,2, Patricia Priegue1,2, Oren Moscovitz1,2, Peter H Seeberger1,2.
Abstract
Malaria, a mosquito-borne disease caused by Plasmodium species, claims more than 400,000 lives globally each year. The increasing drug resistance of the parasite renders the development of new anti-malaria drugs necessary. Alternatively, better delivery systems for already marketed drugs could help to solve the resistance problem. Herein, we report glucose-based ultra-small gold nanoparticles (Glc-NCs) that bind to cysteine-rich domains of Plasmodium falciparum surface proteins. Microscopy shows that Glc-NCs bind specifically to extracellular and all intra-erythrocytic stages of P. falciparum. Glc-NCs may be used as drug delivery agents as illustrated for ciprofloxacin, a poorly soluble antibiotic with low antimalarial activity. Ciprofloxacin conjugated to Glc-NCs is more water-soluble than the free drug and is more potent. Glyco-gold nanoparticles that target cysteine-rich domains on parasites may be helpful for the prevention and treatment of malaria.Entities:
Keywords: Plasmodium falciparum; ciprofloxacin; gold nanoparticles; inhibition; targeting
Mesh:
Substances:
Year: 2020 PMID: 32875786 PMCID: PMC7586288 DOI: 10.1021/acsami.0c09075
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN: 1944-8244 Impact factor: 9.229
Figure 1Synthesis, characterization, and binding efficiency of gold nanoparticles to extracellular malaria parasites. (a) Synthesis of Glc-NCs.[22] (b) TEM image of 2 nm Glc-NCs (scale bar: 50 nm). (c) TEM image of 20 nm Cit-AuNPs (scale bar: 50 nm). (d) ICP-AES detection of Au bound to extracellular parasites showed higher binding efficiency toward Glc-NCs when compared to Cit-AuNPs. ***P ≤ 0.001; ****P ≤ 0.0001.
Figure 2Analysis of the binding of Glc-NCs to different blood stages of P. falciparum. (a) CLSM imaging of ATTO@Glc-NCs incubated for 15 min with infected RBCs showed specific binding of intracellular P. falciparum (red channel, ATTO647N; blue channel, DAPI; scale bar: 5 μm). (b) FACS analysis of the binding of ATTO@Glc-NCs incubated for 15 min with highly synchronized P. falciparum cultures. Parasitemia was determined using SYBR Green (FITC channel), and ATTO647N dye was detected to determine the binding of ATTO@Glc-NCs (APC channel). ****P ≤ 0.0001. (c) CLSM imaging of individual asexual erythrocyte stages incubated with ATTO@Glc-NCs showed specific binding for all the stages (red channel, ATTO647N (ATTO@Glc-NCs); blue channel, DAPI; scale bar: 2 μm).
Figure 3CLSM images of gametocyte blood stages of P. falciparum incubated with ATTO@Glc-NCs (red channel, ATTO647N (ATTO@Glc-NCs); blue channel, DAPI; left scale bars: 2 μm; right scale bars: 5 μm).
Figure 4Synthesis and characterization of Cipro@Glc-NCs. (a) Synthetic scheme for the conjugation of ciprofloxacin to Glc-NCs leading to Cipro@Glc-NCs. (b) TEM imaging of Cipro@Glc-NCs revealed a nanoparticle size of 2 nm (scale bar: 10 nm). (c) Fluorescence spectroscopy showed an emission band at 450 nm for Cipro@Glc-NCs and ciprofloxacin but not for Glc-NCs. d) UV–Vis spectroscopy of Cipro@Glc-NCs revealed bands at 270, 325, and 335 nm corresponding to ciprofloxacin showing successful nanoparticle functionalization.
IC50 Values Obtained from Incubation of Cipro@Glc-NCs, Glc-NCs, Ciprofloxacin, and Artemisinin with P. falciparum for 96 h
| sample | Cipro@Glc-NCs (μM) | ciprofloxacin (μM) | Glc-NCs (μM) | artemisinin (nM) |
|---|---|---|---|---|
| IC50 | 27.4 ± 3.8 | 157.9 ± 58.8 | n.d. | 14.9 ± 6.9 |
n.d. = not determined.